ABSTRACT
Glioblastoma(GBM)is a lethal cancer with limited therapeutic options.Dendritic cell(DC)-based cancer vaccines provide a promising approach for GBM treatment.Clinical studies suggest that other immu-notherapeutic agents may be combined with DC vaccines to further enhance antitumor activity.Here,we report a GBM case with combination immunotherapy consisting of DC vaccines,anti-programmed death-1(anti-PD-1)and poly I:C as well as the chemotherapeutic agent cyclophosphamide that was integrated with standard chemoradiation therapy,and the patient remained disease-free for 69 months.The patient received DC vaccines loaded with multiple forms of tumor antigens,including mRNA-tumor associated antigens(TAA),mRNA-neoantigens,and hypochlorous acid(HOCl)-oxidized tumor lysates.Furthermore,mRNA-TAAAs were modified with a novel TriVac technology that fuses TAAs with a destabilization domain and inserts TAAs into full-length lysosomal associated membrane protein-1 to enhance major histo-compatibility complex(MHC)class Ⅰ and Ⅱ antigen presentation.The treatment consisted of 42 DC cancer vaccine infusions,26 anti-PD-1 antibody nivolumab administrations and 126 poly I:C injections for DC infusions.The patient also received 28 doses of cyclophosphamide for depletion of regulatory T cells.No immunotherapy-related adverse events were observed during the treatment.Robust antitumor CD4+and CD8+T-cell responses were detected.The patient remains free of disease progression.This is the first case report on the combination of the above three agents to treat glioblastoma patients.Our results suggest that integrated combination immunotherapy is safe and feasible for long-term treatment in this patient.A large-scale trial to validate these findings is warranted.
ABSTRACT
Background: Colorectal cancer (CRC) is the third most prevalent type of cancer worldwide, and is one of the major health problems in Asia, Africa, Europe, and America. The tumor antigens recently are of interesting indicators as diagnostic and prognostic tools, The aim of the present study is to detect the expression levels of carbonic anhydrase IX (CA9), the Wilms tumor gene (WT1), and the preferentially expressed antigen in melanoma (PRAME) in the peripheral blood of CRC patients in comparison with healthy controls. Methods: A prospective case-control study of CRC patients was conducted. We included 25 newly-diagnosed CRC eligible patients and obtained peripheral blood samples of them as well as 10 blood samples from the control group. All samples were then submitted to deoxyribonucleic acid (DNA) extraction and a molecular study through real-time polymerase chain reaction (PCR). Results: The CRC group consisted of 15 (60%) female and 10 (40%) male patients with a mean age of 50.52 ± 9.8 years, while the control group included 4 (40%) female and 6 (60%) male patients with a mean age of 47.7 ± 7.9 years. The CRC group, 24 (96%) of patient samples were CA9-positive with strong statistically significant differences (p < 0.00001; sensitivity: 96%; specificity: 90%). Regarding the WT1 gene, there were 11 (44%) positive samples in the CRC group, with no statistically significant differences (p = 0.055; sensitivity: 44%; specificity: 90%). The PRAME gene was positive in 9 (36%) samples in the CRC group, with no statistically significant differences (p = 0.357; sensitivity: 36%; specificity: 80%. Among CA9 (24 patients; 96%) of patients with CRC expressed positive results, in WT1 11(91.6%) CRC patients expressed gene, and in PRAME gene, 9 patients with CRC (81.8%) expressed positive results. Conclusion: Overexpression of the CA9 gene in CRC of high sensitivity and specificity to be used as a tool to discriminate CRC from benign associate with high accuracy compare to WT1 and PRAME genes. (AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Colorectal Neoplasms/diagnosis , Biomarkers, Tumor , WT1 Proteins/genetics , Carbonic Anhydrase IX/genetics , Antigens, Neoplasm/genetics , Prognosis , Case-Control Studies , Gene Expression , Prospective Studies , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
Patients exhibit good tolerance to messenger ribonucleic acid (mRNA) vaccines, and the choice of encoded molecules is flexible and diverse. These vaccines can be engineered to express full-length antigens containing multiple epitopes without major histocompatibility complex (MHC) restriction, are relatively easy to control and can be rapidly mass produced. In 2021, the U.S. Food and Drug Administration (FDA) approved the first mRNA-based coronavirus disease 2019 (COVID-19) vaccine produced by Pfizer and BioNTech, which has generated enthusiasm for mRNA vaccine research and development. Based on the above characteristics and the development of mRNA vaccines, mRNA cancer vaccines have become a research hotspot and have undergone rapid development, especially in the last five years. This review analyzes the advances in mRNA cancer vaccines from various perspectives, including the selection and expression of antigens/targets, the application of vectors and adjuvants, different administration routes, and preclinical evaluation, to reflect the trends and challenges associated with these vaccines.
ABSTRACT
Cancer stem cells (CSCs) with their self-renewal ability are accepted as cells which initiate tumors. CSCs are regarded as interesting targets for novel anticancer therapeutic agents because of their association with tumor recurrence and resistance to conventional therapies, including radiotherapy and chemotherapy. Chimeric antigen receptor (CAR)-T cells are engineered T cells which express an artificial receptor specific for tumor associated antigens (TAAs) by which they accurately target and kill cancer cells. In recent years, CAR-T cell therapy has shown more efficiency in cancer treatment, particularly regarding blood cancers. The expression of specific markers such as TAAs on CSCs in varied cancer types makes them as potent tools for CAR-T cell therapy. Here we review the CSC markers that have been previously targeted with CAR-T cells, as well as the CSC markers that may be used as possible targets for CAR-T cell therapy in the future. Furthermore, we will detail the most important obstacles against CAR-T cell therapy and suggest solutions.
ABSTRACT
Ultrasonography and tests for alpha-fetoprotein are recommended as routine surveillance tools for the early detection of hepatocellular carcinoma (HCC). However, ultrasonography is highly operator dependent and alpha-fetoprotein assays do not yield satisfactory results in diagnosing early stage HCC. Therefore, the development of more sensitive and specific tools for early HCC detection is necessary. Recent studies have shown that tumor-associated antigens (TAAs) elicited by cellular and/or humoral effectors of the immune system are attractive targets for development of diagnostic and therapeutic tools for human cancers including HCC. Most importantly, autoantibodies to TAAs can be detected prior to a clinical diagnosis of HCC. This review focuses on the important features of TAAs and the possible use of autoantibodies to TAAs as biomarkers for early HCC detection.
Subject(s)
Humans , alpha-Fetoproteins , Autoantibodies , Biomarkers , Carcinoma, Hepatocellular , Diagnosis , Immune System , UltrasonographyABSTRACT
Es cada vez mayor la evidencia experimental y clínica de que el sistema inmune interviene activamente en la patogénesis y el control de la progresión tumoral. Una respuesta antitumoral efectiva depende de la correcta interacción de diversos componentes del sistema inmune, como las células presentadoras de antígeno y diferentes sub-poblaciones de células T. Sin embargo, los tumores malignos desarrollan numerosos mecanismos para evadir su reconocimiento y eliminación. Diversos estudios reportan que estructuras asociadas a tumor tales como los antígenos Tn y sialil-Tn se expresan en algunos parásitos protozoarios y helmintos, planteando numerosas interrogantes a nivel de la interacción parásito-hospedador. Considerando que existe una correlación negativa entre ciertas infecciones parasitarias y el desarrollo de cáncer, los antígenos de O-glicosilación incompleta obtenidos de parásitos podrían ser potenciales estructuras miméticas para la inducción de respuestas cruzadas contra antígenos tumorales. Actualmente, el área de la glicobiología del cáncer tiene muchas expectativas para encontrar solución a uno de los grandes problemas de salud que afecta a la población tanto desde el punto de vista económico como social.
There is increasing experimental and clinical evidence that the immune system plays an active role in the pathogenesis and control of tumor progression. An effective antitumor response depends on the correct interaction of the various components of the immune system, such as antigen presenting cells and sub-populations of T cells. However, malignant tumors develop numerous mechanisms to evade recognition and elimination. Several studies report that structures associated with tumors such as Tn and sialyl-Tn antigens are expressed in some protozoan parasites and helminths, thus raising many questions regarding parasite-host interactions. The negative correlation between certain parasite infections and cancer development suggests that antigens from incomplete O-glycosylation obtained from parasites could represent potential mimetic structures for inducing cross responses against tumor antigens. Currently, cancer glycobiology is a promising area in the search for a solution to one of the major health problems affecting the population both from an economic and a social perspective.
ABSTRACT
Durante la carcinogénesis ocurren modificaciones importantes en la glicosilación, entre ellas la elongación incompleta de las cadenas sacarídicas con uniones de tipo O y la exposición de antígenos que en condiciones normales estaban ocultos, los cuales son reconocidos por componentes de la respuesta inmune que promueven o limitan el crecimiento tumoral. Diversos estudios reportan que estructuras asociadas a tumor tales como los antígenos Tn y sialil-Tn se expresan en algunos parásitos protozoarios y helmintos, planteando numerosas interrogantes a nivel de la interacción parásito-hospedador. Considerando que existe una correlación negativa entre ciertas infecciones parasitarias y el desarrollo de cáncer, los antígenos de O-glicosilación incompleta obtenidos de parásitos podrían ser potenciales blancos en la inmunoterapia del cáncer.
During carcinogenesis important modifications in glycosylation occur, among them incomplete elongation of the saccharide chains with type O bonds and the exposure of antigens that were hidden under normal conditions, which are recognized by components of the immune system which promote or limit tumor growth. Several studies report that tumor-associated structures, such as Tn and sialil-Tn, are expressed in some parasites protozoa and helminths, and pose many questions regarding parasite-host interaction. Considering the negative correlation between certain parasite infections and cancer development, antigens from incomplete O-glycosylation obtained from parasites could be potential targets in cancer immunotherapy.
ABSTRACT
Although the success of trastuzumab and rituximab for treatment of breast cancer and non-Hodgkins lymphoma, respectively, suggests that monoclonal antibodies (mAbs) will become important therapeutic agents against a wider range of cancers, useful therapeutic Abs are not yet available for the majority of the human cancers because of our lack of knowledge of which antigens (Ags) are likely to become useful targets. We established a procedure for comprehensive identification of such Ags through the extensive isolation of human mAbs that may be therapeutic. Using the phage-display Ab library we isolated a large number of human mAbs that bind to the surface of tumor cells. They were individually screened by immunostaining, and clones that preferentially and strongly stained the malignant cells were chosen. The Ags recognized by those clones were isolated by immunoprecipitation and identified by mass spectrometry (MS). We isolated 2,114 mAbs with unique sequences and identified 25 distinct Ags highly expressed on several carcinomas. Of those 2,114 mAbs 434 bound to specifically to one of the 25 Ags. I am going to discuss how we could select proper target Ags for therapeutic Abs and candidate clones as therapeutic agents.
Subject(s)
Humans , Antibodies, Monoclonal , Antibodies, Monoclonal, Humanized , Antibodies, Monoclonal, Murine-Derived , Breast Neoplasms , Clone Cells , Immunoprecipitation , Lymphoma, Non-Hodgkin , Mass Spectrometry , Rituximab , TrastuzumabABSTRACT
Although the success of trastuzumab and rituximab for treatment of breast cancer and non-Hodgkins lymphoma, respectively, suggests that monoclonal antibodies (mAbs) will become important therapeutic agents against a wider range of cancers, useful therapeutic Abs are not yet available for the majority of the human cancers because of our lack of knowledge of which antigens (Ags) are likely to become useful targets. We established a procedure for comprehensive identification of such Ags through the extensive isolation of human mAbs that may be therapeutic. Using the phage-display Ab library we isolated a large number of human mAbs that bind to the surface of tumor cells. They were individually screened by immunostaining, and clones that preferentially and strongly stained the malignant cells were chosen. The Ags recognized by those clones were isolated by immunoprecipitation and identified by mass spectrometry (MS). We isolated 2,114 mAbs with unique sequences and identified 25 distinct Ags highly expressed on several carcinomas. Of those 2,114 mAbs 434 bound to specifically to one of the 25 Ags. I am going to discuss how we could select proper target Ags for therapeutic Abs and candidate clones as therapeutic agents.
Subject(s)
Humans , Antibodies, Monoclonal , Antibodies, Monoclonal, Humanized , Antibodies, Monoclonal, Murine-Derived , Breast Neoplasms , Clone Cells , Immunoprecipitation , Lymphoma, Non-Hodgkin , Mass Spectrometry , Rituximab , TrastuzumabABSTRACT
Objective To characterise the alterations of serum autoantibodies for cyclinB1,p62,Koc-IMP1 and survivin in the subjects with esophgeal and gastric cardia carcinoma and precancerous lesion and their expres-sions in the esophageal and gastric cardia cancer tissue.Methods Enzyme-linked immunoassay and tumor-associated antigen mini-array (consisting of five full-length recombinant proteins,including eyefinB1-p62-Koc,IMP1 and Survivin)were applied to determine the serum level of the autoantibodies of these antigens on 376 subjects with e-sephageal and gastric cardia carcinoma and precancerous lesions.At the same time,the expression of these antigens was detected by immunohistochemical method(ABC)on 13 patients with esophageal cancer and 16 with gastric car-dia cancer.Results All of the 5 antigens determined,the linear correlation Was observed for the detection frequency of cyclinB1,IMPI and p62 in esophageal carcinogenesis,and for p62 in gastric cardia multi-stage progression from normal to precancerous and cancerous lesions(P<0.05).The detection rale with single positive antoantibody im-munoreactivity for both esophageal and gastric cardia cancers were low.However.the positive detection mte for both esophageal and gastric cardia cancer increased apparently when the multiple positive markers were combined together for analysis,which increased tO 3～5 and 3～4 folds respectively.Furthermore,the difference in autoantibody immu-noreactive rate was significant with the lesion progressed from mild tO severe precancerous lesions and to cancer both in esophageal and gastric cardia cancers(P<0.05).The positive immunoreactions of the 5 antigens were detected in cancer tissues.The positive immunostaining rates for cyclinB1,Koc,IMP1 and Survivin both in esophageal and gastric cardia cancers were higher compared to their serllin positive rate of autoantibodies I P<0.05).Of the pa-tients with positive immunostaining in the two cancer tissues,the autoantibodies in the serum for the corresponding antigens could be detected in the same patient.Conclusion The production of the tumor-associated autoantibodies is related tO antigens.The screening rate through serum tumor-associated antigen mini-array for the patients with e-sophageal and gastric cardia carcinoma and precancerous lesions has been increased apparently with combined analy-sis of multiple autoantibodies than with single one.